
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Episodes

Thursday Aug 28, 2014
The Year in Biotech So Far and What’s Ahead
Thursday Aug 28, 2014
Thursday Aug 28, 2014
The biotech sector surged in the first half of the year despite volatile markets. M&A and financing continued to be robust as EvaluatePharma weighed in with its Pharma & Biotech Half-Year Report. We spoke to Jonathan Gardner, deputy news editor of EP Vantage, about the trends in the first half of the year, whether 2014 will set new records for M&A activity, and the threats out there that may put an end to the good times.

Thursday Aug 21, 2014
Epirus Sees Opportunities for Biosimilars Outside U.S.
Thursday Aug 21, 2014
Thursday Aug 21, 2014
The regulatory pathway for biosimilars is still a work in progress at the U.S. Food and Drug Administration, but around the world the industry is growing as regulators have resolved issues that remain obstacles in the United States. We spoke to Amit Munshi, CEO of Epirus Biopharmaceuticals, about the opportunities in emerging and developed markets, his company’s strategic approach, and when we’ll see a vibrant biosimilars industry in the United States.

Daniel Levine
Daniel Levine is an award-winning business journalist who has reported on the life sciences, economic development, and business policy issues throughout his career. He is founder and principal of Levine Media Group, host of The Bio Report and RARECast podcasts, a senior fellow at the Center for Medicine in the Public Interest, and author of Global Genes’ annual NEXT report on emerging trends in the world of rare disease. From 2011 to 2014, he served as the lead editor and writer of Burrill & Company’s acclaimed annual book on the biotech industry. His work has appeared in numerous national publications including The New York Times, The Industry Standard, and TheStreet.com.
